Advanced search

Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed follicular lymphoma (FL)

(2011) ANNALS OF ONCOLOGY. 22(suppl. 4). p.187-187
Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
Kimby, E, A Scheliga, J Mayer, Fritz Offner, A Teixeira, K Kuliczkowski, AM Liberati, et al. 2011. “Time to Next Anti-lymphoma Therapy (TTNT) and Treatment-free Interval (TFI) with Bortezomib-rituximab (VCR) Vs Rituximab® in Patients (PTS) with Relapsed Follicular Lymphoma (FL).” In Annals of Oncology, 22:187–187.
APA
Kimby, E., Scheliga, A., Mayer, J., Offner, F., Teixeira, A., Kuliczkowski, K., Liberati, A., et al. (2011). Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed follicular lymphoma (FL). ANNALS OF ONCOLOGY (Vol. 22, pp. 187–187). Presented at the 11th International conference on Malignant Lymphoma.
Vancouver
1.
Kimby E, Scheliga A, Mayer J, Offner F, Teixeira A, Kuliczkowski K, et al. Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab® in patients (PTS) with relapsed follicular lymphoma (FL). ANNALS OF ONCOLOGY. 2011. p. 187–187.
MLA
Kimby, E, A Scheliga, J Mayer, et al. “Time to Next Anti-lymphoma Therapy (TTNT) and Treatment-free Interval (TFI) with Bortezomib-rituximab (VCR) Vs Rituximab® in Patients (PTS) with Relapsed Follicular Lymphoma (FL).” Annals of Oncology. Vol. 22. 2011. 187–187. Print.
@inproceedings{2005591,
  author       = {Kimby, E and Scheliga, A and Mayer, J and Offner, Fritz and Teixeira, A and Kuliczkowski, K and Liberati, AM and Okada, CY and Esseltine, D and Theocharous, P and Zhu, E and Van de Velde, H and Elsayed, YA and Coiffier, B},
  booktitle    = {ANNALS OF ONCOLOGY},
  issn         = {0923-7534},
  language     = {eng},
  location     = {Lugano, Switzerland},
  number       = {suppl. 4},
  pages        = {187--187},
  title        = {Time to next anti-lymphoma therapy (TTNT) and treatment-free interval (TFI) with bortezomib-rituximab (VCR) vs rituximab{\textregistered} in patients (PTS) with relapsed follicular lymphoma (FL)},
  volume       = {22},
  year         = {2011},
}

Web of Science
Times cited: